|Day's Range||7.02 - 7.50|
|52 Week Range||5.90 - 25.17|
|PE Ratio (TTM)||-2.57|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
Roche Holdings has decided to walk away from co-developing NewLink Genetics IDO-inhibitor, GDC-0919.
NewLink (NLNK) needs Investors to pay close attention to the stock based on moves in the options market lately.